Asia-Pacific Minimally Invasive Devices Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4387227
  • Report
  • 116 pages
  • Mordor Intelligence
1 of 3
The Asia-Pacific nuclear medicine market is expected to reach USD 4,274 million by the end of 2019, growing at a CAGR of around 16% from 2014 to 2019.

Nuclear medicine utilizes radioisotopes for application in diagnosis and treatment of diseases. The drugs containing radionuclides are said to be radiopharmaceuticals. Their uses in radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).

Asia-Pacific Nuclear Medicine Market-Market Dynamics

The use of nuclear medicine for diagnostic purposes is gaining importance in the Asia-Pacific region rapidly. There has been increased use of SPECT, PET, CT and MRI for diagnosis of cardiac diseases, brain diseases, cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimerdisease, coronary heart diseases, bone metastasis, different medical conditions affecting the thyroid gland, scar -tissue removal and many cancers.


Some of the factors driving the market are:

Increasing incidence of cancer, thyroidal diseases, endocrinal diseases, and cardiac ailments

Rise in applications of SPECT and PET with advancement of technology

Growing awareness amongst physicians

Public awareness for better healthcare

Emerging economies in Asia-Pacific

Developing healthcare industry


Some of the factors that are limiting the growth of the market are:

Short half-life of radiopharmaceuticals

High capital investment required for development

Stringent regulatory guidelines

Lack of awareness amongst a large patient population


The market offers ample opportunities for market players. Some of these are:

Increasing imaging technologies

Potential radioisotopes in the pipeline

Increasing neurological applications

Increasing cyclotron-based production

The Asia-Pacific nuclear medicine market has been segmented based on type and application. The segmentation based on type of product has been further divided based on diagnostic market and therapeutic market, wherein, the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes that include Rubidium-82, Flourine-18, and the therapeutics category has been segmented into Alpha emitters (Radium-223), Beta Emitters(includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192). The segmentation based on application has been similarly subdivided based on diagnostic and therapeutic application. The diagnostic application includes the application of SPECT and PET in Cardiology, Neurology, Oncology and others. The therapeutic applications include application in Oncology, Thyroid, Endocrinology and various other therapeutic areas.

The Asia-Pacific region has been categorized into China, India, Japan, Australia, New Zealand and South Korea. The Indian and Chinese markets are expected to grow due to the fast growing economy and recent health initiatives taken by the government. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.

Currently, the diagnostics segment holds the largest share in the Asia-Pacific nuclear medicine market in which again SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.

This Report Offers:
Market definition for the Asia-Pacific nuclear medicine market along with identification of key drivers and restraints for the market.

Market analysis for the Asia-Pacific nuclear medicine market, with region-specific assessments and competition analysis.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the Asia-Pacific nuclear medicine market on a regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast period years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry trends
5.1 Current Market Scenario
5.2 Nuclear Medicine Applications
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value chain analysis
5.6 product Lifecycle analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.9 Porter's Five Forces
5.9.1 Bargaining Power of Suppliers
5.9.2 Bargaining Power of Consumers
5.9.3 Threat to new entrants
5.9.4 Threat to substitute products and services
5.9.5 Competitive Rivalry within the industry
6. Drivers, Restraints, Opportunities, and challenges Analysis
6.1 Market Drivers
6.1.1 Increasing incidents of Cancer and Cardiac Ailments
6.1.2 Increasing SPECT and PET applications
6.1.3 Growing awareness amongst Physicians and Public usage of advanced healthcare facilities
6.1.4 Emerging economy in Asia-Pacific
6.1.5 Developing Healthcare industry
6.2 Market Restraints
6.2.1 Short half-life of Radiopharmaceuticals
6.2.2 High Capital Investment
6.2.3 Regulatory Guidelines
6.2.4 Unawareness amongst a huge population
6.3 Opportunities
6.3.1 Increasing Imaging Technologies
6.3.2 Potential Radioisotopes in Pipeline
6.3.3 Increasing Neurological Applications
6.3.4 Cyclotron Based Production
6.3.5 Not well established nuclear medicine market
6.4 Threats
6.4.1 Shutdown of Nuclear Reactors
7. Asia-Pacific Nuclear Medicine Market Segmentation
7.1 Nuclear Medicine Market, by Type of Product
7.1.1 Diagnostic Market SPECT Radioisotopes Technetium-99m (TC-99m) Thallium-201 (Tl-201) Iodine (I-123) Gallium-67 (Ga-67) Others PET Radioisotopes Rubidium-82 Fluorine-18 Others
7.1.2 Therapeutics Market Alpha Emitters Radium-223 (Ra-223) Beta Emitters Iodine-131 (I-131) Samarium-153 (Sm-153) Rhenium-186 (Re-186) Lutetium-177 (Lu-177) Yttrium-90 (Y-90) Others Brachtherapy Iodine-125 (I-125) Cesium-131 (Cs-131) Palladium-103 Iridium-192 Others
7.2 Nuclear Medicine Market, by Application
7.2.1 Introduction
7.2.2 Diagnostics PET Cardiology Neurology Oncology Others SPECT Cardiology Neurology Oncology Others
7.2.3 Therapeutics Oncology Thyroid Endocrinology Others
8. Market segmentation by Geography - Asia-Pacific Share and forecasts
8.1 Asia-Pacific
8.1.1 Introduction
8.1.2 Japan
8.1.3 China
8.1.4 India
8.1.5 Singapore
8.1.6 South Korea
8.1.7 Australia
8.1.8 Rest of Asia-Pacific
9. Competitive Landscape
9.1 Merger and acquisition analysis
9.2 New Product Launches
9.3 Agreements, Collaborations, and Partnerships
10. Key Vendor Analysis
10.1 Mallinckrodt
10.2 Lantheus Medical Imaging
10.3 IBA Group
10.4 Triad Isotope
10.5 Siemens Healthcare
10.6 NTP Radioisotopes
10.7 Cardinal Health, Inc.
10.8 GE Healthcare
10.9 Nordion, Inc.
10.10 Fujifilm Holding Corporation
11. Analyst outlook for Investment opportunities
12. Future Outlook of the market
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown